PTC Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTCT research report →
Companywww.ptcbio.com
PTC Therapeutics, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.
- CEO
- Matthew Klein
- IPO
- 2013
- Employees
- 939
- HQ
- Warren, NJ, US
Price Chart
Valuation
- Market Cap
- $5.89B
- P/E
- -31.39
- P/S
- 7.12
- P/B
- -32.48
- EV/EBITDA
- -245.84
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 77.84%
- Op Margin
- -8.18%
- Net Margin
- -22.58%
- ROE
- 99.84%
- ROIC
- -2.38%
Growth & Income
- Revenue
- $1.73B · 114.51%
- Net Income
- $682.64M · 287.90%
- EPS
- $8.58 · 281.40%
- Op Income
- $856.51M
- FCF YoY
- 486.03%
Performance & Tape
- 52W High
- $87.50
- 52W Low
- $43.17
- 50D MA
- $68.75
- 200D MA
- $67.85
- Beta
- 0.53
- Avg Volume
- 1.25M
Get TickerSpark's AI analysis on PTCT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Boulding Mark Elliott | other | 2,812 |
| May 15, 26 | Boulding Mark Elliott | sell | 2,356 |
| May 15, 26 | Boulding Mark Elliott | sell | 456 |
| May 15, 26 | Boulding Mark Elliott | other | 2,812 |
| May 13, 26 | Klein Matthew B. | other | 12,500 |
| May 14, 26 | Klein Matthew B. | sell | 679 |
| May 14, 26 | Klein Matthew B. | sell | 7,221 |
| May 14, 26 | Klein Matthew B. | sell | 2,100 |
| May 14, 26 | Klein Matthew B. | sell | 2,572 |
| May 8, 26 | Boulding Mark Elliott | other | 2,740 |
Our PTCT Coverage
We haven't published any research on PTCT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PTCT Report →